2025-02-01 - Analysis Report
## Eli Lilly and Co (LLY) Stock Report

**0) Executive Summary:** Eli Lilly and Co (LLY) is a leading pharmaceutical company.  This report analyzes LLY's performance compared to the S&P 500 (VOO), considering its recent price movements, financial indicators, and earnings.  LLY shows significantly higher cumulative returns than VOO, but recent price action suggests some caution.


**1) Performance Comparison with S&P 500 (VOO):**

Eli Lilly and Co. (LLY) is a global pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products.

* **LLY Cumulative Return:** 588.79%
* **VOO Cumulative Return:** 119.91%
* **Return Difference:** 468.9% (468.9% higher than VOO)
* **Relative Divergence:** 74.9% (Indicates LLY's performance is significantly above VOO historically, though not necessarily indicative of future performance).


The table below shows a strong Alpha and significantly higher CAGR for LLY compared to the S&P 500 over several years.  The Beta values show varying levels of market correlation, suggesting its performance doesn't always directly correlate with the broader market.  High CAGR (Compound Annual Growth Rate) numbers, however, should be viewed with caution given they are backward-looking, especially with the high MDD (Maximum Drawdown) values.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 9.0% | 4.3% | -19.0% | -0.0 | 67.9 |
| 2016-2018  | 47.0% | 4.3% | 29.0% | 0.0 | 95.4 |
| 2017-2019  | 60.0% | 8.7% | 29.0% | 1.1 | 110.8 |
| 2018-2020  | 90.0% | 11.1% | 62.0% | 0.3 | 145.2 |
| 2019-2021  | 145.0% | 11.1% | 74.0% | 0.2 | 241.1 |
| 2020-2022  | 196.0% | 11.1% | 188.0% | 0.2 | 323.7 |
| 2021-2023  | 300.0% | 10.8% | 277.0% | 0.3 | 520.8 |
| 2022-2024  | 396.0% | 11.1% | 363.0% | 0.3 | 694.3 |
| 2023-2025  | 345.0% | 11.1% | 284.0% | 0.3 | 729.4 |


**2) Recent Price Movement:**

* **Closing Price:** $811.08
* **Previous Close:** $823.23
* **Change:** -$12.15 (Down 1.48%)
* **5-Day Moving Average:** $810.31
* **20-Day Moving Average:** $777.90
* **60-Day Moving Average:** $783.73

The price is slightly below the 5-day moving average, suggesting recent minor downward pressure.  However, it remains above both the 20-day and 60-day moving averages, indicating a generally upward trend over the medium to long term.


**3) Technical Indicators:**

* **RSI:** 52.57 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.95 (Positive, suggesting bullish momentum)
* **20-Day Relative Divergence Change:** +3.7 (Positive, indicating short-term upward momentum)
* **Expected Return (2+ years):** 112.3% (Significantly higher than the S&P 500 over the long term)

The recent price drop of $12.15, while noticeable, doesn't necessarily signal a significant reversal, given the positive PPO and upward relative divergence.  The high expected return, however, highlights potential, yet still needs to be considered cautiously.


**4) Recent Earnings Analysis:**

The earnings data shows some volatility.  Note the negative EPS in 2023-11-02 and 2024-10-30.  A deeper dive into the reasons for the fluctuations is required for a complete picture. Further analysis is needed to understand the reasons for the fluctuating EPS and revenue numbers.

| Date       | EPS    | Revenue        |
|------------|--------|----------------|
| 2024-10-30 | 1.08   | $11.44 B       |
| 2024-08-08 | 3.29   | $11.30 B       |
| 2024-04-30 | 2.49   | $8.77 B        |
| 2023-11-02 | -0.06  | $9.50 B        |
| 2024-10-30 | -0.06  | $9.50 B        |


**5) Financial Information:**

The financial data showcases high profitability (profit margin consistently above 80%) and significant equity.  However, Return on Equity (ROE) fluctuates considerably, highlighting the need for more in-depth analysis to understand these variations.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $11.44B | 81.02% |
| 2024-06-30 | $11.30B | 80.80% |
| 2024-03-31 | $8.77B  | 80.91% |
| 2023-12-31 | $9.35B  | 80.88% |
| 2023-09-30 | $9.50B  | 80.42% |

**Capital and Profitability:**

| Quarter | Equity    | ROE     |
|---------|-----------|---------|
| 2024-09-30 | $14.24B  | 6.81%   |
| 2024-06-30 | $13.56B  | 21.88%  |
| 2024-03-31 | $12.81B  | 17.51%  |
| 2023-12-31 | $10.77B  | 20.33%  |
| 2023-09-30 | $11.22B  | -0.51%  |


**6) Overall Analysis:**

LLY has significantly outperformed the S&P 500 over the long term, showcasing high growth and profitability.  However, recent price action suggests a potential short-term slowdown. The high expected return remains attractive for long-term investors, but a thorough understanding of the fluctuating EPS and ROE is crucial.  Further investigation into the reasons behind the earnings volatility and the drivers of ROE changes is necessary before making any investment decisions.  Consider diversifying your portfolio, and consult a financial advisor before making investment decisions.
